Manama: The National Health Regulatory Authority (NHRA) today approved the emergency use of the EVUSHELD, to combat the COVID-19, making Bahrain the first country to utilize the drug.
The drug will be available to adults 18 years and above, who are immunocompromised or who are taking immunosuppressive drugs, or for individuals with occupations that put them at risk of infection.
The decision follows the evaluation of data provided by the manufacturer AstraZeneca, carried out by the NHRA’s Pharmaceutical Products Regulation department.
EVUSHELD is made from a mixture of two antibodies, which achieved a “statistically significant decrease in cases of acute or fatal COVID-19 infection” in patients who were not hospitalized and those with symptoms ranging from mild to moderate.
